Plus Therapeutics (NASDAQ:PSTV) Receives Buy Rating from D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Plus Therapeutics (NASDAQ:PSTV) in a research report sent to investors on Thursday morning,Benzinga reports. The brokerage currently has a $5.00 target price on the stock.

A number of other research analysts have also weighed in on PSTV. Maxim Group reduced their price objective on Plus Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a research report on Monday, August 18th. Wall Street Zen raised Plus Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Saturday, August 16th. HC Wainwright reduced their price target on Plus Therapeutics from $5.50 to $3.00 and set a “buy” rating for the company in a report on Friday, June 27th. Ascendiant Capital Markets upped their price target on shares of Plus Therapeutics from $20.00 to $20.50 and gave the stock a “buy” rating in a research note on Thursday, June 5th. Finally, D Boral Capital upgraded shares of Plus Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, September 3rd. One research analyst has rated the stock with a Strong Buy rating and four have issued a Buy rating to the company. According to MarketBeat, Plus Therapeutics presently has a consensus rating of “Buy” and an average price target of $7.88.

Plus Therapeutics Price Performance

Shares of NASDAQ PSTV opened at $0.56 on Thursday. Plus Therapeutics has a 1 year low of $0.16 and a 1 year high of $2.31. The firm has a 50-day moving average of $0.52 and a 200 day moving average of $0.56. The stock has a market cap of $55.88 million, a P/E ratio of -0.25 and a beta of 0.66.

Plus Therapeutics (NASDAQ:PSTV) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($0.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.08. The business had revenue of $1.39 million during the quarter, compared to analysts’ expectations of $1.08 million. Research analysts expect that Plus Therapeutics will post -2.3 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Robert P. Lenk purchased 110,000 shares of the company’s stock in a transaction dated Friday, August 22nd. The shares were purchased at an average price of $0.49 per share, with a total value of $53,900.00. Following the acquisition, the director directly owned 139,327 shares in the company, valued at $68,270.23. The trade was a 375.08% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.79% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Plus Therapeutics stock. Virtu Financial LLC bought a new stake in Plus Therapeutics, Inc. (NASDAQ:PSTV) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 40,030 shares of the company’s stock, valued at approximately $38,000. Virtu Financial LLC owned 0.24% of Plus Therapeutics as of its most recent filing with the Securities & Exchange Commission. 3.28% of the stock is owned by hedge funds and other institutional investors.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.